Követés
Hajnalka Lőrincz
Hajnalka Lőrincz
Ismeretlen szervezet
E-mail megerősítve itt: belklinika.com
Cím
Hivatkozott rá
Hivatkozott rá
Év
Association of chemerin with oxidative stress, inflammation and classical adipokines in non‐diabetic obese patients
P Fülöp, I Seres, H Lőrincz, M Harangi, S Somodi, G Paragh
Journal of cellular and molecular medicine 18 (7), 1313-1320, 2014
972014
High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus
K Gaál, T Tarr, H Lőrincz, V Borbás, I Seres, M Harangi, P Fülöp, ...
Lipids in health and disease 15, 1-8, 2016
682016
Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects
H Lőrincz, M Katkó, M Harangi, S Somodi, K Gaál, P Fülöp, G Paragh, ...
Clinical endocrinology 81 (3), 370-377, 2014
502014
Plasminogen Activator Inhibitor‐1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects
S Somodi, I Seres, H Lőrincz, M Harangi, P Fülöp, G Paragh
International Journal of Endocrinology 2018 (1), 9596054, 2018
382018
HDL subfraction distribution and HDL function in untreated dyslipidemic patients
M Harangi, A Szentpéteri, B Nádró, H Lőrincz, I Seres, D Páll, G Paragh
undefined 1, 166-173, 2017
212017
Effects of alpha-lipoic acid treatment on serum progranulin levels and inflammatory markers in diabetic neuropathy
B Nádró, H Lőrincz, Á Molnár, A Szentpéteri, E Zöld, I Seres, D Páll, ...
Journal of International Medical Research 49 (5), 03000605211012213, 2021
202021
Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications
N Zsíros, P Koncsos, H Lőrincz, I Seres, M Katkó, A Szentpéteri, VE Varga, ...
Clinical biochemistry 49 (12), 862-867, 2016
202016
Serum obestatin level strongly correlates with lipoprotein subfractions in non-diabetic obese patients
A Szentpéteri, H Lőrincz, S Somodi, VE Varga, G Paragh, I Seres, ...
Lipids in Health and Disease 17, 1-8, 2018
172018
Crucial regulatory role of organokines in relation to metabolic changes in non-diabetic obesity
H Lőrincz, S Somodi, B Ratku, M Harangi, G Paragh
Metabolites 13 (2), 270, 2023
162023
Clinical aspects of genetic and non-genetic cardiovascular risk factors in familial hypercholesterolemia
E Berta, N Zsíros, M Bodor, I Balogh, H Lőrincz, G Paragh, M Harangi
Genes 13 (7), 1158, 2022
152022
Afamin levels and their correlation with oxidative and lipid parameters in non-diabetic, obese patients
I Juhász, S Ujfalusi, I Seres, H Lőrincz, VE Varga, G Paragh Jr, S Somodi, ...
Biomolecules 12 (1), 116, 2022
152022
Paraoxonase-1 and myeloperoxidase correlate with vascular biomarkers in overweight patients with newly diagnosed untreated hyperlipidaemia
A Szentpéteri, N Zsíros, VE Varga, H Lőrincz, M Katkó, I Seres, P Fülöp, ...
Vasa 46 (5), 370-376, 2017
122017
Low Levels of Serum Fetuin-A and Retinol-Binding Protein 4 Correlate with Lipoprotein Subfractions in Morbid Obese and Lean Non-Diabetic Subjects
H Lőrincz, I Csige, M Harangi, A Szentpéteri, I Seres, Z Szabó, G Paragh, ...
Life 11 (9), 881, 2021
102021
Determination of serum progranulin in patients with untreated familial hypercholesterolemia
B Nádró, H Lőrincz, L Juhász, A Szentpéteri, F Sztanek, É Varga, D Páll, ...
Biomedicines 10 (4), 771, 2022
92022
Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia
VE Varga, H Lőrincz, N Zsíros, P Fülöp, I Seres, G Paragh, J Balla, ...
Lipids in Health and Disease 15, 1-7, 2016
92016
Role of altered metabolism of triglyceride-rich lipoprotein particles in the development of vascular dysfunction in systemic lupus erythematosus
Á Diószegi, H Lőrincz, E Kaáli, P Soltész, B Perge, É Varga, M Harangi, ...
Biomolecules 13 (3), 401, 2023
82023
Changes in serum afamin and vitamin E levels after selective LDL apheresis
VE Varga, H Lőrincz, A Szentpéteri, L Juhász, I Seres, G Paragh Jr, ...
Journal of clinical apheresis 33 (5), 569-575, 2018
62018
Characterization of a novel high-density lipoprotein antioxidant capacity assay and its application to high-density lipoprotein fractions
K Gaál, H Lőrincz, I Seres, M Harangi, AV Oláh, G Paragh
Clinical Biochemistry 46 (9), 825-827, 2013
52013
Impaired organokine regulation in non-diabetic obese subjects: halfway to the cardiometabolic danger zone
H Lőrincz, B Ratku, S Csiha, I Seres, Z Szabó, G Paragh, M Harangi, ...
International Journal of Molecular Sciences 24 (4), 4115, 2023
42023
Sphingosine 1-phosphate and apolipoprotein M levels and their correlations with inflammatory biomarkers in patients with untreated familial hypercholesterolemia
L Juhász, H Lőrincz, A Szentpéteri, B Nádró, É Varga, G Paragh, ...
International Journal of Molecular Sciences 23 (22), 14065, 2022
42022
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20